knowledge -WSS

knowledge

author：leisure time 2025-10-01 00:46:09 - browse：77141

Sage Therapeutics, a biotech developing an experimental treatment for postpartum depression, this week trumpeted strong results from a clinical trial, which cheered investors and pushed up its stock price. But outside the lab, the company’s aggressive efforts to raise awareness of postpartum depression have proved divisive.

The campaign’s message: “When it comes to postpartum depression, silence sucks.” It features close-up photos of distressed, tearful women who can’t speak — because they have pacifiers stuck in their mouths.

The images have been plastered on bus stops, buses, conference booths, and on a dedicated website. The ads don’t specifically mention Sage’s drug, which still needs further testing before the company can bring it to the Food and Drug Administration for possible approval. Instead, they urge women to talk “openly and honestly” about postpartum depression. An estimated 600,000 women in the U.S. alone experience symptoms, which range from insomnia and irritability to difficulty bonding with their baby.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： Why health workers in Gaza are injured or die at high rates

entertainment

WSS

Hospital price transparency does save money, advocate argues

Researchers explore possible ties between long Covid, menopause

Group behind ProMed defends move to subscription

Chris Christie meets with Zelenskyy during Ukraine trip

STAT Summit: Biotech founders on deal

Senate committee scrutinizes Medicare Advantage brokers

knowledge

knowledge

knowledge

Medical records are filled with copy

STAT Summit: Biotech founders on deal

Supreme Court strikes down use of affirmative action

STAT Readout Newsletter: Today's biggest biotech updates

Medical records are filled with copy

2023 STAT Wunderkinds: get to know the winners

Drug repurposing or repositioning? The language matters

FAA sets up new process for Hawaii air tour operators to fly at lower altitudes after fatal crashes

Psychedelics group wrestles with new pharma identity

Lawmakers consider Medicare pay reforms for doctors

hotspot

Group behind ProMed defends move to subscription

Physicians aren't 'burning out.' They're suffering from moral injury

H.R. 3 is the wrong path to lower drug costs

Late stage cancers on the rise after pandemic delayed screenings

FDA struggles to regulate food additives, sometimes for decades

NIH confirmation hearing shows politicization of research

hotspot

entertainment

explore

leisure time